| |
ctrl
|
Without FBS
|
csf-1r siRNA
|
Non-coding siRNA
|
CSF-1 25 ng/ml
|
CSF-1 50 ng/ml
|
CSF-1 100 ng/ml
|
|---|
|
CMT-U27
|
72.10
|
73.4
|
15.65***
|
75.80
|
99.85***
|
99.80***
|
99.65***
|
|
CMT-U309
|
66.80
|
70.0
|
3.00***
|
64.40
|
99.75*
|
99.85*
|
99.65*
|
|
P114
|
88.70
|
73.7
|
38,45***
|
90.85
|
99.80*
|
99.80*
|
99.90*
|
|
CMT-W1
|
80.45
|
73.6
|
23.45***
|
82.30
|
99.55**
|
99.55**
|
99.75**
|
|
CMT-W2
|
58.70
|
52.3
|
23.15***
|
64.80
|
99.35***
|
99.10***
|
99.55***
|
- The number of CSF-1R expressing cells obtained with FACS Aria II (Becton Dickinson). The number of cells which express CSF-1R is significantly decreased after the csf-1r specific siRNA treatment and significantly increased after treatment with CSF-1 at the dose of 25, 50 and 100 ng/ml (no significant differences between these doses have been observed). Treatment of cells with non-coding siRNA did not cause any effect. The experiment has been conducted in three replicates. P<0.05 was regarded as significant and marked as *, whereas p<0.01 and p<0.001 was regarded as highly significant and marked as * and ***, respectively. One-way ANOVA followed by Tukey HSD post-hoc test were applied.
